Non-alcoholic fatty liver disease in irritable bowel syndrome: More than a coincidence?

Authors: Purssell H, Whorwell PJ, Athwal VS, et al.
Published in World J Hepatol 2021
Recently, there has been interest in the apparent co-incidence of NAFLD in patients with IBS mainly driven by improved understanding of their shared risk factors and pathophysiology H. Purssell et al. (Manchester University NHS Foundation Trust, UK)......
Read More

Non-invasive risk stratification in NAFLD/NASH patients for screening esophagogastroduodenoscopy

Authors: J, Abdelfattah T, Manka PP, et al.
Published in Clin Exp Gastroenterol 2022
J. Romano et al. (Medical University of South Carolina, Charleston, USA) evaluated whether these non-invasive markers and/or any other clinical parameters may be used to identify patients with liver cirrhosis who are likely to have large....
Read More

New targets for NAFLD

Authors: Parlati L, Régnier M, Guillou H, et al.
Published in JHEP Rep 2021
NAFLD is a growing cause of chronic liver disease worldwide. Several preclinical models (dietary and genetic animal models) of NAFLD have deepened our understanding of its aetiology and pathophysiology. Despite the progress made, there are currently no effective treatments for NAFLD...
Read More

NASH Epidemic: a call to action

Authors: Kanwal F, Shubrook JH, Younossi Z, et al.
Published in Gastroenterology 2021
NAFLD and NASH are common conditions with a rising burden. As pointed out by F. Kanwal et al. (Baylor College of Medicine, and Michael E. DeBakey Veterans Affairs Medical Center, Houston,USA), “yet there are significant management gaps between clinical guidelines and practice in patients with NAFLD and NASH. Further, there is no single...
Read More

Phytomedicines in experimental models of NAFLD

Authors: Ore A, Akinloye OA.
Published in Medicina (Kaunas) 2021
This systematic review aims to investigate the potential multi-targeting effects of plant-derived extracts in experimental models of NAFLD. The authors, A. Ore et al., (Ajayi Crowther University, Oyo, and Federal University of Agriculture, Abeokuta, Nigeria) identified 9 articles fulfilling their inclusion criteria...
Read More

Liver organoid cultures and development of new therapeutic agents

Authors: Yamamoto H, Usui T, Sasaki K.
Published in Nihon Yakurigaku Zasshi 2021
In this review in Japanese, H. Yamamoto et al. (Tokyo University of Agriculture and Technology, Japan) outline the current issues in the diagnosis and treatment of NASH and introduce their research for the discovery of early diagnostic markers and the development of new therapeutic agents using liver organoid cultures derived from mouse models of NASH...
Read More

Physical activity, cardiorespiratory fitness and NAFLD

Authors: Kerr CJ, Waterworth SP, Brodie D, et al.
Published in J Gastroenterol Hepatol 2021
High levels of physical activity and cardiorespiratory fitness may protect against NAFLD. C. J. Kerr et al. (University of Essex, UK) investigated whether different physical activity intensities, and cardiorespiratory fitness, were independent predictors of non-alcoholic fatty liver disease...
Read More

Meta-analysis: NAFLD and melatonin supplementation

Authors: Mansoori A, Salimi Z, Hosseini SA, et al.
Published in Complement Ther Med 2020
This meta-analysis was conducted to evaluate the effect of melatonin on liver indices in patients with NAFLD. The results showed that melatonin had a significant effect on aspartate aminoteransferase , alkaline phosphatase, and gamma-glutamyltransferase, but no significant effect on alanine aminotransferase...
Read More